Weng Lu-Chen, Cushman Mary, Pankow James S, Basu Saonli, Boerwinkle Eric, Folsom Aaron R, Tang Weihong
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55454, USA.
Departments of Medicine and Pathology, University of Vermont, Burlington, VT 05405, USA.
Hum Mol Genet. 2015 Apr 15;24(8):2401-8. doi: 10.1093/hmg/ddu732. Epub 2014 Dec 30.
Reduced activated partial thromboplastin time (aPTT) is a risk marker for incident and recurrent venous thromboembolism (VTE). Genetic factors influencing aPTT are not well understood, especially in populations of non-European ancestry. The present study aimed to identify aPTT-related gene variants in both European Americans (EAs) and African Americans (AAs). We conducted a genetic association study for aPTT in 9719 EAs and 2799 AAs from the Atherosclerosis Risk in Communities (ARIC) study. Using the Candidate Gene Association Resource (CARe) consortium candidate gene array, the analyses were based on ∼50 000 SNPs in ∼2000 candidate genes. In EAs, the analyses identified a new independent association for aPTT in F5 (rs2239852, P-value = 1.9 × 10(-8)), which clusters with a coding variant rs6030 (P-value = 7.8 × 10(-7)). The remaining significant signals were located on F5, HRG, KNG1, F11, F12 and ABO and have been previously reported in EA populations. In AAs, significant signals were identified in KNG1, HRG, F12, ABO and VWF, with the leading variants in KNG1, HRG and F12 being the same as in the EAs; the significant variant in VWF (rs2229446, P-value = 1.2 × 10(-6)) was specific to the AA sample (minor allele frequency = 19% in AAs and 0.2% in EAs) and has not been previously reported. This is the first study to report aPTT-related genetic variants in AAs. Our findings in AAs demonstrate transferability of previously reported associations with KNG1, HRG and F12 in EAs. We also identified new associations at F5 in EAs and VWF in AAs that have not been previously reported for aPTT.
活化部分凝血活酶时间(aPTT)缩短是新发和复发性静脉血栓栓塞症(VTE)的一个风险标志物。影响aPTT的遗传因素尚未完全明确,尤其是在非欧洲血统人群中。本研究旨在识别欧洲裔美国人(EA)和非裔美国人(AA)中与aPTT相关的基因变异。我们对社区动脉粥样硬化风险(ARIC)研究中的9719名EA和2799名AA进行了aPTT的遗传关联研究。使用候选基因关联资源(CARe)联盟的候选基因芯片,分析基于约2000个候选基因中的约50000个单核苷酸多态性(SNP)。在EA中,分析确定F5基因中一个与aPTT新的独立关联(rs2239852,P值 = 1.9×10⁻⁸),它与一个编码变异rs6030聚集在一起(P值 = 7.8×10⁻⁷)。其余显著信号位于F5、HRG、KNG1、F11、F12和ABO基因上,此前已在EA人群中报道过。在AA中,在KNG1、HRG、F12、ABO和VWF基因中识别到显著信号,KNG1、HRG和F12中的主要变异与EA中的相同;VWF基因中的显著变异(rs2229446,P值 = 1.2×10⁻⁶)是AA样本特有的(在AA中的次要等位基因频率为19%,在EA中为0.2%),且此前未被报道。这是第一项报道AA中与aPTT相关基因变异的研究。我们在AA中的发现证明了此前在EA中报道的与KNG1、HRG和F12的关联具有可转移性。我们还在EA的F5基因和AA的VWF基因中识别到了此前未报道的与aPTT相关的新关联。